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Abstract
Background: De novo truncating and splicing mutations in the additional sex combs-like 3 (ASXL3) gene have
been implicated in the development of Bainbridge-Ropers syndrome (BRPS) characterised by severe developmental
delay, feeding problems, short stature and characteristic facial features.
Case presentation: We describe, for the first time, a patient with severe short stature, learning difficulties, feeding
difficulties and dysmorphic features with a novel compound heterozygous mutation in ASXL3.Additionally the
patient also has primary insulin like growth factor-1 (IGF1) deficiency. The mutations occur in exon 11 and proximal
part of exon 12 and are strongly conserved at the protein level across various species. In-silico analyses using
PolyPhen-2 and SIFT predict the amino acid substitutions to be potentially deleterious to the protein function.
Detailed bioinformatics analysis show that the molecular defects caused by the two compound heterozygous
mutations synergistically impact on two points of the molecular interaction network of ASXL3.
Conclusion: We hypothesise that ASXL3 potentially has a role in transcriptional activation of IGF1 involved in
signalling pathways that regulate cell proliferation and growth, which could be contributing to short stature
encountered in these patients.
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Background
The use of next generation sequencing in children with
undiagnosed or unidentified syndromic disorders is
becoming more popular in recent years, increasing the
diagnostic ability and discovery of novel genes and
mutations contributing to novel clinical phenotypes.
Bainbridge-Ropers syndrome (BRPS: OMIM #615485)
was described for the first time by Bainbridge and his col-
leagues in the year 2013 [1]. BRPS is caused by de-novo
truncating mutations in the additional sex combs-like 3
(ASXL3) gene giving rise to characteristic phenotypic
features such as short stature, severe intellectual deficit,
feeding difficulties, failure to thrive and cranio-facial
features. BRPS has been reported in 27 patients in the
literature so far [1–4]. The majority of the patients had
frameshift or truncating mutations in ASXL3. One patient
has been reported to have a splicing mutation in ASXL3
resulting in BRPS [3].
Bohring-Opitz syndrome (BOS: OMIM#605039) is a de-
velopmental syndrome characterised by a severe intellectual
deficit, distinct posture and cranio-facial abnormalities,
feeding problems and failure to thrive [5]. BOS is caused by
de novo truncating mutations in ASXL1, which belongs to
the same family as ASXL3 [5]. BOS and BRPS have been
found to have some overlap of their clinical phenotypes.
We describe, for the first time, a patient, with severe
short stature secondary to IGF1 (Insulin Growth Factor 1)
deficiency, developmental delay, intellectual deficit, cranio-
facial abnormalities due to a novel compound heterozygous
mutation in ASXL3 identified by whole exome sequencing.
Case presentation
The patient is a 16-year-old Caucasian British boy born
at full term following an induction of labour to non-
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consanguineous Caucasian healthy British parents. The
antenatal scans were normal and the birth weight was
4.1 kg (1.84 SDS). He was admitted to the neonatal unit
due to respiratory distress. Whilst in the neonatal unit, he
had persistent feeding difficulties and required tube feeding.
He was noted to have scaphocephaly that required surgical
fixation at 4 months of age. He also developed severe con-
stipation from 5 weeks of age requiring daily bowel wash-
outs from 18 months of age and colostomy at 3 years. He
had bilateral undescended testes requiring orchidopexy. He
has global developmental delay and complex learning diffi-
culties requiring additional support at school. He also has
been diagnosed with autism. At 7 years of age, he was re-
ferred to endocrinology for assessment of his severe short
stature (−4.11 SDS for height, mid parental height: −1.1
SDS, weight: -2.30 SDS). He has dysmorphic features in-
cluding prominent long nasal bridge and forehead, small
lower jaw, thin lips, low set cupped ears, strabismus and
down-slanting palpebral fissures (Fig. 1). He was found to
have a normal growth hormone (GH) response (peak GH
11.7 μg/L) (Normal:>6.7 μg/L) to an arginine stimulation
test. He had a bone age delay of 3 years and the IGF1 was
persistently low at 4.9 nmol/L (−3.2 SDS). TSH (Thyroid
stimulating hormone), Free T4 (thyroxine), ACTH (Adreno
corticotrophic hormone), prolactin and cortisol concentra-
tions were all within the normal range. A trial of rhGH
(recombinant human growth hormone) (50 μg/kg/day) for
a period of 1 year was ineffective in improving height
velocity (Fig. 2a). An IGF1 (insulin growth factor-1) gener-
ation test after 33 μg/kg of rhGH did not produce any re-
sponse. Subsequently, recombinant IGF1 (rIGF1) therapy
(mecasermin) was commenced at 12.5 years which resulted
in improvement of height velocity to -3SDS (Fig. 2a). He
has a normal muscle tone and normal deep tendon reflexes.
His cranial MRI scan of brain and spine were normal. The
hearing has been normal. The echocardiogram and renal
ultrasound did not identify any abnormalities. The plasma
amino acids, urine organic acids, pyruvic acid analysis were
within the normal limits. CGH microarray did not reveal
any copy number changes. Targeted sequencing of IGF1,
IGF1R and GHR did not reveal any mutations. Currently,
the patient continues to require rIGF1 therapy to support
growth. The weight gain continues to be suboptimal (Fig.
2b).
Material and methods
This study was given favourable ethical opinion by the
North West - Liverpool Central Research Ethics Commit-
tee (REC Reference: 15/NW/0758) and site study approval
was granted by the Clinical Research Business Unit at
Alder Hey Children’s NHS Foundation Trust, Liverpool,
UK. Informed and written consent was obtained from the
parents. DNA was extracted from blood samples of the
child and both the biological parents (trio). Exons were
captured using SureSelect XT Human All Exon V5 cap-
ture library and DNA sequencing was carried out using
the Illumina HiSeq4000 at 2 × 150 bp paired-end sequen-
cer. The sequence data were aligned to the reference
genome (GRCh37/hg19). The variants present in at least
1% minor allele frequency in 1000 Genomes Project,
dbSNP142, and NHLBI ESP exomes were excluded. The
predicted deleterious variants included non-synonymous
coding, splice site, frameshift, stop gain variants.
Results
Two novel heterozygous mutations in ASXL3 [NM_0
30632.1]: c.2965C > G, p.R989G inherited from the
mother and c.3078G > C, p.K1026 N, inherited from the
father were found in the patient. The mutations were sub-
sequently confirmed by Sanger sequencing (Fig. 3). The
mutations occur in exon 11 and proximal part of exon
12(Fig. 4). Multiple sequence alignment visualisation using
the UCSC Genome Browser showed that both mutated
positions are strongly conserved at the protein level across
vertebrates as diverse as lemur, bat, fish and frog, implying
that mutation could potentially affect the protein structure
or function. In silico analyses using PolyPhen-2 and SIFT
predict the amino acid substitutions to be potentially
deleterious to the protein function.
Discussion
Loss of function mutations in ASXL3 in the form of de-
novo truncating dominant mutations and splicing muta-
tion have been implicated in BRPS. Here we report for the
first time, a compound heterozygous ASXL3 mutation in a
patient with BRPS-like features and associated with pri-
mary IGF1 deficiency. Pathogenic mutations in ASXL3
have been reported to occur predominantly in exon 11
and proximal part of exon 12. All the described mutations
retain the ASXN and ASXH domains. The compound
heterozygous mutations in our patient also lie on exon 11
and proximal exon 12, retaining the ASXN and ASXH do-
mains similar to previously described mutations (Fig. 4).
Fig. 1 Dysmorphic features: prominent long nasal bridge and
forehead, small lower jaw, thin lips, strabismus, down slanting
palpebral fissures and low set cupped ears
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Fig. 2 a Height and its response to GH and IGF1 treatment. b Weight
Fig. 3 Electropherograms showing the compound heterozygous mutations
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Both these mutations occur on the conserved ASXM1
domain in ASXL3 (Fig. 4). Both the variants are extremely
rare and have a population frequency < 0.01, as indicated
from the ExAC browser. The synergistic effect of both of
these rare mutations potentially contributes to the loss of
function of the protein contributing to the BRPS like
phenotype. Our patient has multiple dysmorphic features
that overlap with those described in previous reported
cases of BRPS such as short stature, failure to thrive, feed-
ing difficulties, cranio-facial features, developmental delay
and learning difficulties (Table 1).
ASXL3 belongs to the gene family of ASXL genes, the
mammalian homologues of Drosophila Asx. ASXL includes
three orthologues: ASXL1, ASXL2 and ASXL3 that encode
the Putative Polycomb group (PcG) protein that has a role
in regulating the homeotic genes (Hox) [6]. PcG proteins
can act either as transcriptional repressors or activators of
Hox genes [6]. The genes in the ASXL family share a com-
mon domain architecture consisting of ASXN, ASXH,
ASXM1, ASXM2 domains and a PHD finger, and act by
forming complexes with other proteins via methylation of
histones [4, 6, 7]. ASXL3 has been implicated in the deubi-
quitination of histone H2A lysine 119(H2AK119Ub1), a
component of the polycomb repressive deubiquitination
(PR-DUB) complex [4]. The formation of PR-DUB complex
is critical for normal function. ASXL3 interacts with BAP1,
a ubiquitin terminal hydroxylase and removes the mono-
ubiquitin (Ub1) from the H2AK119Ub1 [8]. Patients with
BRPS have been found to have a significant increase in the
H2AK119Ub1 in their fibroblasts because of the impaired
deubiquitination [4]. ASXL3 has a similar expression pat-
tern in human tissues as ASXL1 but at a relatively lesser
levels, which may explain the overlap of some phenotypic
features seen in BRPS and BOS [9]. Within the human
brain, ASXL3 expression has been found within the white
matter, insula, cingulate gyrus and amygdala [10]. The
spinal cord, kidney, bone marrow and liver also express
ASXL3, but at a lower level when compared to ASXL1 [9].
Detailed bioinformatics analysis suggests a possible mo-
lecular mechanism by which the first of the mutations
R989G would lead to a functional defect. A scan against
the ELM(Eukaryotic Linear Motif) database shows a stretch
of amino-acid residues from the position 989 to 997 within
the wild-type ASXL3 that matches with an interaction
motif (LIG_14–3-3_CanoR_1; Accession ELME000417)
that describes canonical phosphopeptide binding motif of
14–3-3 group of proteins. 14–3-3 proteins are important
cell regulators [11], best known for their role in cell cycle
control. The mutated Arginine at position 989 together
with a phosphorylated Serine residue, 3–5 residues down-
stream are the main determinants of interaction with 14–3-
3 proteins. These proteins are also characterised as histone
modification readers [12]. This links suggestively to the
recently determined role of ASXL3 in histone deubiquitina-
tion [4]. According to this hypothesis, mutation of R989 to
glycine would prevent the interaction of ASXL3 with an as-
yet unidentified 14–3-3 protein, thereby damaging function
through impairing its ability to scaffold epigenetic protein
complexes [6]. Although the molecular mechanism of the
second mutation K1026 N, is unclear it is possible that this
mutation affects phosphorylation of ASXL3 through its
location within recognition motifs for kinases (PIKK group,
motif from 1024 to 1030 or GSK3, motif from 1024 to
1031); The molecular defects caused by the two mutations
would specify the disorder additively or synergistically by
simultaneously impacting on two points of the molecular
interaction network of ASXL3 contributing to its loss of
function.
The association of primary IGF1 deficiency in BRPS has
not been described before. IGF-1 is a 70-amino acid pep-
tide hormone and growth factor that is structurally hom-
ologous to proinsulin [13]. In normal individuals, IGF-1
circulates as part of a ternary complex with a molecular
weight of 150 kDa. The complex consists of IGF-1, an
acid-labile subunit (ALS), and a protein that binds IGF-1
(IGFBP-3). Primary IGF1 deficiency is defined as basal
Fig. 4 ASXL3 gene with domains. 1–12 represents the exon numbers. Some of the previously reported mutations (frameshift and truncating) and
splice site mutations have been shown. Compound heterozygous mutations in our patient have been highlighted in bold
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IGF-1 and height of ≤ -3 SDS with normal or elevated
levels of GH [13]. The primary action of IGF1 is mediated
by binding to its specific receptor, the insulin-like growth
factor 1 receptor (IGF1R), which is present in many
tissues. IGF1R is a receptor tyrosine kinase and binding of
IGF1 to IGF1R initiates intracellular signalling. IGF-1 is
Table 1 Phenotypic comparison between our patient and other reported patients with BRPS
Phenotype Our Patient Bainbridge et al. [1].
4 patients
Dinwiddie et al. [2].
1 patient
Srivastava et al. [4].
3 patients
Hori et al. [3].
1 patient
Balasubramanian






+ + + + + 9/12 6/6
Failure to thrive + + + + + 3/6
Short stature + + ND + 2/12 2/6
IUGR − 3/4 + 2/3 + −
Craniofacial
Trigonocephaly − 1/4 + 1/3 + ND ND
Microcephaly − 2/4 + − + + 1/6
Scaphocephaly + − − − − + ND




+ 2/4 ND 1/3 ND + 5/6








Nasal bridge long − depressed Broad (1/3) depressed long, prominent 6/6 (prominent
columella)
Low set ears + 1/4 NA 1/3 − + ND
Posteriorly
rotated ears
Cupped ears 2/4 + + − + ND
Anteverted
nares
− + + 1/3 − ND 5/6
Small chin + ND ND 2/3 + + ND
Ophthalmic
Strabismus + ND ND 1/3 + 7/12 5/6




+ + + + + 12/12 6/6
Intellectual
deficit
+ + + 2/3 + 12/12 5/6
Seizures − − + 1/3 3/12 2/6





+ 1/4 ND ND ND ND ND
Undescended
testes
+ 1/4 ND ND ND ND ND
Chronic
constipation
+ ND ND 1/3 ND ND ND
ND: not described. +: present. -: absent
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one of the most potent natural activators of the Akt sig-
nalling pathway, which stimulates cellular growth and pro-
liferation [14].
Transcriptome analysis of ASXL3 fibroblasts from patients
with BRPS examining the differentially expressed genes
(DEGs) has shown that the genes regulating the cellular pro-
liferation are downregulated [4]. IGF1 plays a vital role in ac-
tivating the Akt signalling pathway, a potent stimulator for
cell proliferation and growth [15]. We therefore hypothesise
that ASXL3 potentially has a role in transcriptional activa-
tion of IGF1 involved in this pathway potentially via epigen-
etic mechanisms [16], which could be contributing to short
stature encountered in these patients.
Conclusions
The compound heterozygous mutations potentially contrib-
ute to the loss of function in ASXL3, causing a phenotype
similar to BRPS. Although with our current knowledge, the
molecular interaction between ASXL3 and IGF1 is unclear,
it may important to look for IGF1 deficiency in the patients
with ASXL3mutation.
Consent
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